A Lux, H Llacer, F Heussen, AM Joussen - British Journal of Ophthalmology, 2007 - bjo.bmj.com Methods: Forty-three patients with visual loss due to neovascular age-related
macular disease (ARMD) (44 eyes) underwent intravitreal injections of 1.25 mg
(0.05 ml) bevacizumab and were followed up every 4 weeks for 2, 3 or 6 ... Cited by 9 - Related articles - BL Direct - All 3 versions
A Lux, H Llacer, FMA Heussen… - Br J Ophthalmol, 2007 - bjo.bmj.com Anja Lux, Helene Llacer, Florian MA Heussen, et al. ... Articles on similar
topics can be found in the following collections ... Non-responders to
bevacizumab (Avastin) therapy of ... Anja Lux, Helene Llacer, Florian MA ... Related articles - All 2 versions
J Levy, M Shneck, S Rosen, I Klemperer, D … - International Ophthalmology, 2009 - Springer Abstract Objective To report the visual and anatomic outcome of intravitreal
bevacizumab (Avastin) injec- tions in the treatment of subfoveal neovascular
age-related macular degeneration (AMD). Methods Interventional, ... Cited by 5 - Related articles - All 2 versions
- ►prsjournal.com [PDF] KC Madhusudhana, SR Hannan, CPR Williams, … - British Medical Journal, 2007 - bjo.bmj.com J Lotery, AJ Luff and RSB Newsom KC Madhusudhana, SR Hannan, CPR Williams, SV
Goverdhan, C Rennie, A ... 118 cases age-related macular degeneration: results
from treatment of choroidal neovascularization in Intravitreal bevacizumab ( ... Cited by 6 - Related articles - All 5 versions
RV Azad, MA Khan, B Chanana, S Azad - Japanese Journal of Ophthalmology, 2008 - Springer Exudative age-related macular degeneration (AMD) is a major cause of legal
blindness in the elderly worldwide.1,2 Hitherto, the standard treatment options
were laser photo- coagulation and photodynamic therapy, both of which have ... Cited by 8 - Related articles - All 2 versions
- ►duanesolution.com IA FALKENSTEIN, L Cheng, VL MORRISON, … - Retina, 2007 - journals.lww.com IRYNA A. FALKENSTEIN, MD, LINGYUN CHENG, MD, VICTORIA L. MORRISON, MD, IGOR
KOZAK, MD, AJAY M. TAMMEWAR, MD, WILLIAM R. FREEMAN, MD ... Purpose: To compare
standardized visual outcomes and macular thickness changes associated with ... Cited by 18 - Related articles - BL Direct - All 6 versions
- ►prsjournal.com [PDF] N Nigam, J Hedaya, WR Freeman - British Medical Journal, 2008 - bjo.bmj.com LB Cantor Correspondence to: LB Cantor, Department of Ophthalmology, Indiana
University School of Medicine, Indianapolis, IN 46202, USA; lcantor@iupui.edu
Funding: Supported in part by an unrestricted research grant from the ... Related articles - All 5 versions
S Jyothi, H Chowdhury, M Elagouz, S … - Eye, 2009 - nature.com The current medical environment demands that quality health care is delivered at
an affordable cost through the use of objective, unbiased clinical data. This
study was undertaken to review the current literature on bevacizumab for ... Related articles - All 3 versions
M Nagpal, K Nagpal, V Mehta - Indian Journal of Ophthalmology, 2009 - pubmedcentral.nih.gov The efficacy of intravitreal anti-vascular endothelial growth factor (VEGF)
agents for treatment of choroidal neovascular membranes (CNVMs) of varying
etiologies as the first line of treatment, has been adequately proven by ... Related articles - All 4 versions
AM Joussen, D Wong, P Walter, B Kirchhof, J … - Eye, 2009 - nature.com Patients suffering from visual loss because of AMD were randomised to either
surgery or a control group receiving standard treatment (observation or
photodynamic therapy (PDT)). The primary end point was the change of visual ... Related articles - All 3 versions
